

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

### SECTION 1. IDENTIFICATION

Product name : Ezetimibe / Atorvastatin Formulation

#### Manufacturer or supplier's details

Company name of supplier : Organon & Co.  
Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302  
Telephone : 1-551-430-6000  
Emergency telephone : 1-215-631-6999  
E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical  
Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Specific target organ toxicity : Category 2 (Liver, muscle)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.  
H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements :

#### Prevention:

P260 Do not breathe dust.

#### Response:

P314 Get medical attention if you feel unwell.

#### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	$\geq 20 - < 30$
Atorvastatin	134523-03-8	$\geq 10 - < 20$
Ezetimibe	163222-33-1	$\geq 1 - < 5$
Magnesium stearate	557-04-0	$\geq 1 - < 5$

Actual concentration is withheld as a trade secret

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : Wash with water and soap.  
Get medical attention if symptoms occur.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.  
Contact with dust can cause mechanical irritation or drying of the skin.  
Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

- Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NOx)  
Fluorine compounds  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

inert or nuisance dust      50 Million particles per cubic foot  
Value type (Form of exposure): TWA (total dust)  
Basis: OSHA Z-3

15 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (total dust)  
Basis: OSHA Z-3

5 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

15 Million particles per cubic foot  
Value type (Form of exposure): TWA (respirable fraction)  
Basis: OSHA Z-3

Dust, nuisance dust and particulates      10 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (Total dust)  
Basis: CAL PEL

5 mg/m<sup>3</sup>  
Value type (Form of exposure): PEL (respirable dust fraction)  
Basis: CAL PEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable)	5 mg/m <sup>3</sup>	NIOSH REL
		TWA (total)	10 mg/m <sup>3</sup>	NIOSH REL
		TWA (total dust)	15 mg/m <sup>3</sup>	OSHA Z-1
		TWA (respirable fraction)	5 mg/m <sup>3</sup>	OSHA Z-1

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

Atorvastatin	134523-03-8	TWA	0.05 mg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm <sup>2</sup>	Internal
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA (Inhalable particulate matter)	10 mg/m <sup>3</sup>	ACGIH
		TWA (Respirable particulate matter)	3 mg/m <sup>3</sup>	ACGIH

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

**Respiratory protection** : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

### Hand protection

**Material** : Chemical-resistant gloves

**Remarks** : Consider double gloving.

**Eye protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	off-white
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	0.01 g/l
Partition coefficient: n-	:	No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

octanol/water

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

### Atorvastatin:

Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg  
LD50 (Mouse, male and female): > 5,000 mg/kg

### Ezetimibe:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
LD50 (Mouse): > 5,000 mg/kg  
LD50 (Dog): > 3,000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 2,000 mg/kg  
Application Route: Intraperitoneal  
LD50 (Mouse): > 1,000 - < 2,000 mg/kg  
Application Route: Intraperitoneal

### Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Atorvastatin:

Species : Rabbit  
Result : No skin irritation

#### Ezetimibe:

Species : Rabbit  
Result : No skin irritation

#### Magnesium stearate:

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### **Atorvastatin:**

Species : Rabbit  
Result : No eye irritation  
Method : Draize Test

##### **Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

##### **Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials

### Respiratory or skin sensitization

#### **Skin sensitization**

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

#### Components:

##### **Atorvastatin:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

##### **Ezetimibe:**

Test Type : Maximization Test  
Species : Guinea pig  
Result : negative

##### **Magnesium stearate:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Method : OECD Test Guideline 406  
Result : negative  
Remarks : Based on data from similar materials

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

#### Atorvastatin:

Genotoxicity in vitro : Test Type: reverse mutation assay  
Test system: Salmonella typhimurium  
Result: negative

Test Type: reverse mutation assay  
Test system: Escherichia coli  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster lung cells  
Result: negative

Test Type: sister chromatid exchange assay  
Test system: Chinese hamster lung cells  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

#### Ezetimibe:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Metabolic activation: with and without metabolic activation  
Result: negative

Test Type: Chromosomal aberration  
Test system: Human lymphocytes  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

Application Route: Oral  
Result: negative

### **Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

#### **Atorvastatin:**

Species : Mouse, male and female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
NOAEL : 200 mg/kg body weight  
LOAEL : 400 mg/kg body weight  
Result : negative  
Target Organs : Liver

Species : Rat, female  
Application Route : oral (gavage)  
Exposure time : 2 Years  
LOAEL : 100 mg/kg body weight  
Target Organs : Musculo-skeletal system

#### **Ezetimibe:**

Species : Rat, female  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

Species : Rat, male  
Application Route : oral (feed)

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

Exposure time : 104 weeks  
Result : negative

Species : Mouse  
Application Route : oral (feed)  
Exposure time : 104 weeks  
Result : negative

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Atorvastatin:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, female  
Fertility: NOAEL: 225 mg/kg body weight  
Result: No effects on fertility.

Test Type: Fertility/early embryonic development  
Species: Rat, male  
Fertility: NOAEL: 175 mg/kg body weight  
Result: No effects on fertility.

Effects on fetal development : Species: Rat, female  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: No teratogenic effects., Embryo-fetal toxicity.  
Remarks: Maternal toxicity observed.

Species: Rabbit, female  
Application Route: Oral  
Developmental Toxicity: NOAEL: 100 mg/kg body weight  
Result: No embryo-fetal toxicity.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

### Ezetimibe:

- Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rat, male and female  
Fertility: NOAEL: > 1,000 mg/kg body weight  
Result: No effects on fertility., No fetotoxicity.
- Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.
- Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.

### Magnesium stearate:

- Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials
- Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

### Components:

#### Atorvastatin:

- Routes of exposure : Ingestion  
Target Organs : Liver, muscle  
Assessment : May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

### Repeated dose toxicity

#### Components:

##### **Cellulose:**

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

##### **Atorvastatin:**

Species : Rat, male and female  
LOAEL : 70 mg/kg  
Application Route : oral (gavage)  
Exposure time : 52 Weeks  
Target Organs : Liver

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : oral (gavage)  
Exposure time : 104 Weeks  
Target Organs : Liver

##### **Ezetimibe:**

Species : Dog  
NOAEL : 1,000 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 1,500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Mouse  
NOAEL : 500 mg/kg  
Application Route : Oral  
Exposure time : 90 d  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 300 mg/kg  
Application Route : Oral  
Exposure time : 1 y  
Remarks : No significant adverse effects were reported

##### **Magnesium stearate:**

Species : Rat  
NOAEL :  $> 100$  mg/kg  
Application Route : Ingestion

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

Exposure time : 90 Days  
Remarks : Based on data from similar materials

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Ezetimibe:

Not applicable

### Experience with human exposure

### Components:

#### Atorvastatin:

Ingestion : Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

#### Ezetimibe:

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

### Components:

#### Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

#### Atorvastatin:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 92 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 200 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): 108 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 14 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.49 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.2 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition

### Ezetimibe:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210

NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l  
Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.



# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

---

NOEC: 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

### Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l  
Exposure time: 48 h  
Method: DIN 38412  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l  
Exposure time: 47 h  
Test substance: Water Accommodated Fraction  
Method: Directive 67/548/EEC, Annex V, C.2.  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials  
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l  
Exposure time: 72 h  
Test substance: Water Accommodated Fraction  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l  
Exposure time: 16 h  
Test substance: Water Accommodated Fraction  
Remarks: Based on data from similar materials

### Persistence and degradability

#### Components:

##### Cellulose:

Biodegradability : Result: Readily biodegradable.

##### Atorvastatin:

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 7.7 %  
Exposure time: 28 d  
Method: OECD Test Guideline 314

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

---

### Ezetimibe:

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111

### Magnesium stearate:

Biodegradability : Result: Not biodegradable  
Remarks: Based on data from similar materials

### Bioaccumulative potential

#### Components:

##### Atorvastatin:

Partition coefficient: n-octanol/water : log Pow: 1.62

##### Ezetimibe:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

##### Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

### Mobility in soil

#### Components:

##### Atorvastatin:

Distribution among environmental compartments : log Koc: 2.84

##### Ezetimibe:

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106

### Other adverse effects

No data available

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
N.O.S.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,  
N.O.S.  
(Ezetimibe, Atorvastatin)

Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### 49 CFR

UN/ID/NA number : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014

(Ezetimibe, Atorvastatin)  
Class : 9  
Packing group : III  
Labels : CLASS 9  
ERG Code : 171  
Marine pollutant : yes(Ezetimibe, Atorvastatin)  
Remarks : Above applies only to containers over 119 gallons or 450 liters.  
Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## SECTION 15. REGULATORY INFORMATION

### CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

### SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

### SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

**SARA 311/312 Hazards** : Combustible dust  
Specific target organ toxicity (single or repeated exposure)

**SARA 313** : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

### US State Regulations

#### Pennsylvania Right To Know

Cellulose	9004-34-6
D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate	64044-51-5
Lactose	63-42-3
Atorvastatin	134523-03-8
Croscarmellose sodium	74811-65-7

#### California List of Hazardous Substances

Polyvinyl pyrrolidone	9003-39-8
-----------------------	-----------

#### California Permissible Exposure Limits for Chemical Contaminants

Cellulose	9004-34-6
Magnesium stearate	557-04-0

### The ingredients of this product are reported in the following inventories:

AICS : not determined

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version 8.1      Revision Date: 09/29/2023      SDS Number: 26504-00021      Date of last issue: 04/04/2023  
Date of first issue: 10/29/2014


DSL : not determined

IECSC : not determined

### SECTION 16. OTHER INFORMATION

#### Further information

##### NFPA 704:



##### HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
CAL PEL : California permissible exposure limits for chemical contaminants (Title 8, Article 107)  
NIOSH REL : USA. NIOSH Recommended Exposure Limits  
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants  
OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts  
ACGIH / TWA : 8-hour, time-weighted average  
CAL PEL / PEL : Permissible exposure limit  
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek  
OSHA Z-1 / TWA : 8-hour time weighted average  
OSHA Z-3 / TWA : 8-hour time weighted average

AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;

# SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



ORGANON

## Ezetimibe / Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/04/2023
8.1	09/29/2023	26504-00021	Date of first issue: 10/29/2014

ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/29/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8